This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mantovani, G. Articles by Serpe, R. Search for Related Content PubMed PubMed Citation Articles by Mantovani, G. Articles by Serpe, R.

Cancer-Related Anorexia/Cachexia Syndrome and Oxidative Stress: An Innovative Approach beyond Current Treatment

Department of Medical Oncology, University of Cagliari, Cagliari, Italy

Requests for reprints: Giovanni Mantovani, Cattedra e Divisione di Oncologia Medica, Università di Cagliari, Policlinico Universitario, Presidio di Monserrato, Strada Statale 554, bivio Sestu, 09042 Cagliari, Italy. Phone/Fax: 39-70-60-28-6253. E-mail: mantovan{at}pacs.unica.it

Objective: Cancer-related anorexia/cachexia syndrome and oxidative stress play a key role in the progression and outcome of neoplastic disease. Patients and Methods: On the basis of our previously published studies and clinical experience, we have developed an innovative approach consisting of diet with high polyphenol content (400 mg), p.o. pharmaconutritional support enriched with n – 3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) 2 cans (237 mL each) per day, medroxiprogesterone acetate 500 mg/d, antioxidant treatment with -lipoic acid 300 mg/d plus carbocysteine lysine salt 2.7 g/d plus vitamin E 400 mg/d plus vitamin A 30,000 IU/d plus vitamin C 500 mg/d, and selective cyclooxygenase-2 inhibitor Celecoxib 200 mg/d. The treatment is administered for 16 weeks. The following variables are evaluated: (a) clinical variables (stage and Eastern Cooperative Oncology Group performance status); (b) nutritional variables (lean body mass, appetite, and resting energy expenditure); (c) laboratory variables (serum levels of proinflammatory cytokines, C-reactive protein, and leptin and blood levels of reactive oxygen species and antioxidant enzymes); and (d) quality of life variables (European Organization for Research and Treatment of Cancer QLQ-C30, EQ-5D_index, and EQ-5D_VAS). A phase II nonrandomized study has been designed to enroll 40 patients with advanced cancer at different sites with symptoms of cancer-related anorexia/cachexia syndrome and oxidative stress. Results: As of January 2004, 28 patients have been enrolled: 25 patients were evaluable and 14 of them have completed the treatment (20 patients have completed 2 months of treatment). As for clinical response, five patients improved, three patients remained unchanged, and six patients worsened. The Eastern Cooperative Oncology Group performance status (grade) 1 remained unchanged. As for nutritional/functional variables, the lean body mass increased significantly at 2 and 4 months. As for laboratory variables, reactive oxygen species decreased significantly and proinflammatory cytokines interleukin-6 and tumor necrosis factor- decreased significantly. As for quality of life, it comprehensively improved after treatment. Conclusions: The treatment has been shown to be effective for clinical response, increase of lean body mass, decrease of reactive oxygen species and proinflammatory cytokines, and improvement of quality of life. The treatment has been shown to be safe with good compliance of patients. The study is in progress (14 further patients will be included).

This article has been cited by other articles:

				M. J. Ryan, H. J. Dudash, M. Docherty, K. B. Geronilla, B. A. Baker, G. G. Haff, R. G. Cutlip, and S. E. Alway Aging-Dependent Regulation of Antioxidant Enzymes and Redox Status in Chronically Loaded Rat Dorsiflexor Muscles J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2008; 63(10): 1015 - 1026. [Abstract] [Full Text] [PDF]

				G. Mantovani, A. Maccio, C. Madeddu, G. Gramignano, M. R. Lusso, R. Serpe, E. Massa, G. Astara, and L. Deiana A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1030 - 1034. [Abstract] [Full Text] [PDF]

				R. Siddiqui, D. Pandya, K. Harvey, and G. P. Zaloga Nutrition Modulation of Cachexia/Proteolysis Nutr Clin Pract, April 1, 2006; 21(2): 155 - 167. [Abstract] [Full Text] [PDF]

				W. Droge Oxidative stress and ageing: is ageing a cysteine deficiency syndrome? Phil Trans R Soc B, December 29, 2005; 360(1464): 2355 - 2372. [Abstract] [Full Text] [PDF]